Redmile Group LLC recently announced the acquisition of new stake in Adc Therapeutics SA (NYSE:ADCT). The institutional investor has increased its shareholding in the Healthcare company by 0.91% to 14.18 million shares with purchase of 0.13 million shares. This fresh investment now brings its stake to 15.92% valued currently at $11.77 million. In addition, Millennium Management LLC raised its holdings by 1.23 million to 2.65 million shares. And Affinity Asset Advisors LLC has lifted its position by 83.33% or 0.5 million shares – to 1.1 million shares.
With over 0.49 million Adc Therapeutics SA (ADCT) shares trading Friday and a closing price of $1.48 on the day, the dollar volume was approximately $0.72 million. The shares have shown a negative half year performance of -26.00% and its price on 12/22/23 gained nearly 15.63%. Currently, there are 80.64M common shares owned by the public and among those 55.88M shares have been available to trade.
The top 3 mutual fund holders in Adc Therapeutics SA are AlphaCentric LifeSci Healthcare F, Pictet – Biotech, and iShares Biotechnology ETF. AlphaCentric LifeSci Healthcare F owns 1.07 million shares of the company’s stock, all valued at over $0.89 million. The company bought an additional 0.29 million shares recently to bring their total holdings to about 1.20% of the shares outstanding. iShares Biotechnology ETF sold 2244.0 shares to bring its total holdings to over 0.4 million shares at a value of $0.33 million. iShares Biotechnology ETF now owns shares totaling to 0.45% of the shares outstanding.
Shares of Adc Therapeutics SA (NYSE: ADCT) opened at $1.30, up $0.02 from a prior closing price of $1.28. However, the script later moved the day high at 1.4991, up 15.63%. The company’s stock has a 5-day price change of -6.92% and 83.06% over the past three months. ADCT shares are trading -61.46% year to date (YTD), with the 12-month market performance down to -51.32% lower. It has a 12-month low price of $0.36 and touched a high of $5.75 over the same period. ADCT has an average intraday trading volume of 512.19K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 30.91%, 70.59%, and -4.76% respectively.
Institutional ownership of Adc Therapeutics SA (NYSE: ADCT) shares accounts for 48.30% of the company’s 80.64M shares outstanding. Mutual fund holders own 3.01%, while other institutional holders and individual stakeholders account for 40.74% and — respectively.
It has a market capitalization of $119.35M and a beta (3y monthly) value of 1.38. The earnings-per-share (ttm) stands at -$2.19. Price movements for the stock have been influenced by the stock’s volatility, which stands at 17.38% over the week and 17.35% over the month.
Analysts forecast that Adc Therapeutics SA (ADCT) will achieve an EPS of $Agree Realty Corporation for the current quarter, $62.52 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $ADC Therapeutics SA while analysts give the company a high EPS estimate of $Arcturus Therapeutics Holdings . Comparatively, EPS for the current quarter was $Adaptive Biotechnologies Corpor a year ago. Earnings per share for the fiscal year are expected to decrease by -17.89%, and 29.16% over the next financial year. EPS should shrink at an annualized rate of 15.80% over the next five years, compared to 85.26% over the past 5-year period.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 5 brokerage firm advisors rate Adc Therapeutics SA (ADCT) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 2 Wall Street analysts polled rate the stock as a buy, while 2 of the 5 advise that investors “hold,” and 0 rated it as a “Sell.”
